Shifting Focus in Ophthalmic Clinical Research

Publish Date:
May 1, 2012
David Hoelscher, MD, and Nicholas Spittal, MBA, PMP

There have been significant advancements in the treatment of eye diseases in the past decade as vascular endothelial growth factor (VEGF) inhibitors have become standard of care for many retina indications. There will continue to be incremental improvements for these areas. But there remain critical unmet needs for those with other common eye disorders. This peer-reviewed article discusses novel approaches for glaucoma/ocular hypertension and dry eye disease where there is significant mid-phase clinical research activity. Scientists and doctors are continuing to seek treatments that impact these diseases at their root, rather than just the symptoms.